Mylan asks SCOTUS to end NHK-Fintiv rule
ricochet64 / Shutterstock.com
The European Patent Office (EPO) has invalidated and revoked a patent related to Teva’s multiple sclerosis drug Copaxone (glatiramer acetate injection), in a win for Mylan.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
EPO, Copaxone, Mylan, patent invalidation, Teva, multiple sclerosis, Technical Board of Appeal, litigation, big pharma, commercial actions